Purchase Order 75F40122P00216
Award Date 9/29/22
Potential Completion Date 10/29/23
Potential Value $342K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services Food and Drug Administration awarded a $533,378 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for delivery of one Illumina NextSeq 2000 Sequencing System to support the agency's microbial metagenomics research in Berwyn Heights, Maryland. The original solicitation requested an integrated genomic sequencing system, including the NextSeq 2000 or equivalent, to generate sequence data, perform real-time...
- The Department of Health and Human Services Food and Drug Administration awarded a $169,505.48 firm fixed price purchase order to Illumina, Inc. of Laurel, Maryland for an Illumina NextSeq 50 System Check. The contract has a period of performance through February 10, 2025 to deliver product care services for the NextSeq 50 sequencing system. No set-aside provisions were applied to this award made by the FDA to support its regulatory and public health responsibilities through genomic analysis...
- The Department of Health and Human Services Food and Drug Administration awarded a $457,531.00 firm fixed price purchase order to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract is for the delivery of an ILLUMINA NEXTSEQ 2000 SEQUENCING SYSTEM, plus a preventative maintenance agreement, to be performed in Silver Spring, Maryland. This award does not have a set-aside designation. Illumina has a history of providing sequencing systems and related...
- This contract is for the acquisition of the NEXTSEQ 2000 SEQUENCING SYSTEM by the Department of Health and Human Services Food and Drug Administration. The $432,031.00 firm fixed price contract was awarded to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract has a completion date of November 12, 2025 and does not have a set-aside designation. Illumina has previously been awarded prime contracts by federal agencies such as the...
- <p>The Food and Drug Administration awarded a purchase order to Illumina, Inc. valued at $268,947 on July 13, 2026, for NextSeq sequencing system service contract. Work is performed in San Diego, California. The order is firm fixed price with an ultimate completion date of July 22, 2031.</p>
- The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $265,200 purchase order to Illumina, Inc. to deliver one NextSeq 2000 sequencing system, a one-year DRAGEN software license, and installation services. The sequencing system and software will replace aging equipment and reduce costs while enabling continued use of validated protocols to support the Center for Cellular Engineering's research efforts. The single award was made on a non-competitive...
- The U.S. Food and Drug Administration awarded a $219,300 firm fixed price purchase order to Illumina, Inc. for a NextSeq 2000 Sequencing System. This award was not subject to any set-aside provisions. Illumina is a manufacturer of sequencing and genomic analysis instruments and reagents that has been awarded past federal contracts with agencies such as the NIH, CDC, USDA, and VA to provide a range of sequencing systems and related products. The award references an original small business...
- The Department of Health and Human Services Food and Drug Administration awarded a $19,283.10 firm fixed price purchase order to Illumina, Inc. to provide Illumina ISEQ 100 Systems. The ISEQ 100 Systems will be used for quality control and rebalancing of samples in sample pools. The systems are compatible with Illumina's library preparation kits and provide fast, cost-effective small-scale runs. The place of performance is Illumina's facilities in San Diego, California, and the period of...
- This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for the provision of a NextSeq 500 Sequencing System, with a ceiling value of $292,000.00 and a completion date of September 23, 2016. The contract does not have a set-aside designation. Illumina has previously been awarded prime federal contracts and subcontracts by various...
- The Food and Drug Administration awarded a $439,247.56 firm fixed-price purchase order to Illumina, Inc. on July 15, 2024, for the procurement of an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System. The award encompasses the sequencing instrument itself, trade-in credit for an existing NextSeq 500 unit, installation services, operator training, warranty coverage, and a preventative maintenance agreement. The system will be delivered to and installed at the FDA's Center for...